Abstract: Azathioprine (AZA), a thiopurine drug, is widely used in the treatment of children with immunological diseases such as inflammatory bowel disease (IBD) and autoimmune hepatitis (AIH); however, interindividual variability in the occurrence of adverse drug reactions (ADRs) and drug response is observed. This study investigated (i) the relationships between inosine triphosphate pyrophosphatase (ITPA) activity, an enzyme involved in thiopurine metabolism, and the occurrence of ADRs in children with immunological disease on AZA therapy, and (ii) the relationship between ITPA activity and the inflammatory activity observed in children with IBD. ITPA and TPMT activities were determined in 106 children with immunological disease on AZA therapy. Markers of hepatotoxicity, myelotoxicity, pancreatitis and inflammation as well as clinical information were retrospectively collected during regular medical visits. No significant association was found between ITPA activity and hepatotoxicity or clinical ADRs such as cutaneous reactions, arthralgia, flulike symptoms and gastrointestinal disorders. Concerning myelotoxicity, a significant relation was observed between ITPA activity and RBC mean corpuscular volume (MCV; p=0.003). This observation may be related to the significant relationship found between high ITPA activity and the increase in c-globulin level reflecting inflammation (p=0.005). In our study, ITPA activity was not associated with occurrence of ADRs, but a relationship between high ITPA activity and c-globulin, a marker of inflammation, was found in children with IBD. Therefore, measurement of ITPA activity may help to identify children with IBD predisposed to residual inflammation on AZA therapy. Further prospective studies are needed to confirm this result.
The thiopurine drug, azathioprine (AZA), is a well-established immunomodulator agent used successfully in the treatment of children with inflammatory bowel disease (IBD), autoimmune hepatitis (AIH) and other immunological diseases. AZA, an inactive prodrug, is converted into 6-mercaptopurine (6-MP) and then metabolized by a multi-enzymatic process to produce the active 6-thioguanine nucleotides (6-TGN) [1] and by thiopurine S-methyltransferase (TPMT; EC 2.1.167) to produce the 6-methylmercaptopurine nucleotides (6-MeMPN). However, despite having good clinical efficacy, adverse drug reactions (ADRs) such as bone marrow suppressions, hepatitis, pancreatitis and cutaneous reactions occur frequently and often require dose reduction or discontinuation of therapy [2] . The occurrence of these ADRs is, at least in part, determined by genetic polymorphisms of enzymes involved in the extensive metabolism of thiopurine drugs. Among the most discussed polymorphisms, single nucleotide polymorphisms (SNPs) of genes coding TPMT and inosine triphosphate pyrophosphatase (ITPA; EC 3.6.1.19) are frequently suggested [3, 4, 5] .
TPMT polymorphism explains only 30% to 60% of all cases with thiopurine intolerance [6] . Among various other possible candidate enzymes involved in the metabolism of thiopurines, ITPA has been associated with the occurrence of adverse events (ADRs) in patients treated with AZA or 6-MP in phenotypic [2, 7, 8] and genotypic studies [2, 8, 23] .
ITPA catalyses the conversion of inosine triphosphate (ITP) to inosine monophosphate (IMP) preventing the accumulation of ITP and dITP (deoxyITP) in normal cells [14, 22, 24] . In ITPA-deficient patients treated with AZA or 6-MP, accumulation of 6-thioinosine triphosphate (6-TITP) [14, 22, 25] and/or 6-methylthioinosine triphosphate (6-MeTITP) [26] , the major component of 6-MeMPN [27] [28] [29] , is suggested, resulting in thiopurine drugs toxicity. Recently, in a previous study on children with immunological diseases, we found a negative correlation between ITPA activity and 6-MeMPN concentrations, suggesting that a decrease in ITPA activity may be a risk factor to the accumulation of 6-MeMPN in cells [30] .
The most important mutations, associated with decreased enzyme activity, are 94C > A and IVS2 + 21A > C [31] , which exhibit a frequency of 6% and 13%, respectively, in Caucasian populations [25, 32, 33] . Recently, we have demonstrated that ITPA phenotype shows a quadrimodal distribution in the paediatric population with low, intermediate, normal and high activity [30] .
The potential implication of ITPA in the occurrence of ADRs of AZA has been investigated. However, a number of contradictory results have been reported, from an impact of ITPA polymorphism on toxicity [2, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] to no significant association [26, [34] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] . This issue remains unresolved, and no obvious statement about the benefit of introducing ITPA assay into clinical practice is currently available [24, 45, 46] . Despite the fact that phenotyping, as opposed to genotyping, is predictive of ITPA activity as it considers physiopathological status, co-prescribed drugs and also allows the detection of variation in ITPA activity independent of whether it is caused by novel mutations [31] , the great majority of studies are based on genotyping of the most important mutation (94C > A and IVS2 + 21A > C).
To our knowledge, no data from paediatric populations with immunological diseases are available on the relationship between ITPA activity and the occurrence of ADRs on AZA therapy. The aim of this study was to evaluate the relationships between ITPA activity and the occurrence of ADRs in children with immunological disease treated with AZA and to investigate the relation between ITPA activity and the inflammatory response observed in children with IBD.
Materials and Methods
Study subjects. This retrospective study was performed in a paediatric population of 106 children using the database of the Lyon University Hospital (France). Children (age <18 years) with immune diseases referred to the clinical pharmacokinetic unit in relation to thiopurine therapy for TPMT analysis and therapeutic drug monitoring based on 6-TGN and 6-MeMPN assays were recruited. Patient data were recorded during the period from March 2011 to March 2015. Only patients with a stable dose of AZA for at least 2 months before measurements of laboratory parameters and clinical records were included to ensure equilibration of treatment [47] . Samples from patients with evidence of poor compliance confirmed by clinicians with total nucleotide levels (6-TGN + 6-MeMPN) below 150 pmol/8 9 10 8 RBCs were excluded [47] . Likewise, patients who had received blood transfusions within 3 months were not included. Clinical information including age, gender, bodyweight, diagnosis, daily AZA dosage and duration of thiopurine drugs therapy were collected. Clinical occurrence of ADRs was obtained from medical records. Laboratory parameters such as ITPA and TPMT activities, normalized metabolite concentrations of 6-TGN and 6-MeMPN levels (per mg azathioprine per kg), aspect of supernatant, hepatic parameters (aspartate and alanine aminotransferase (AST and ALT), c-glutamyl transpeptidase (GGT), alkaline phosphatase (ALP) and total bilirubin), haematological parameters (white blood cell (WBC) count, neutrophil count, lymphocyte count, platelet count, RBC count and mean corpuscular volume (MCV)), inflammatory markers (serum C-reactive protein (CRP), c-globulin, platelet count, WBC count and fibrinogen) and pancreatic parameters (lipase serum activity) were collected during regular visits. All these laboratory parameters and clinical information were collected in a time period of 1 month before or after collection of blood sampling for ITPA and TPMT assays. These data were extracted retrospectively from the laboratory database and the medical charts.
Definition of adverse drug reactions. Hepatotoxicity was defined as at least one of the following parameters (i) over the upper limit of its normal range for GGT, ALP and total bilirubin and (ii) greater than twice the upper normal limit for AST and ALT except for haemolysed specimens (data excluded). Patients with liver diseases were excluded from the analysis of the relation between ITPA activity and hepatotoxicity.
Myelotoxicity was defined as a decrease below the lower limit of the respective reference ranges used by the Lyon University Hospital laboratory according to age (table S1) of WBC markers including WBC, neutrophil and lymphocyte counts and/or platelet count and/or RBC markers including RBC count and MCV. Because haemoglobin is used to normalize ITPA activity, this parameter was not included in the analyses.
Pancreatitis was defined by lipase serum activity greater than onethird of the upper normal limit.
Clinical ADRs recorded were as follows: gastrointestinal disorders by the presence of diarrhoea, nausea or vomiting; cutaneous reactions by skin reactions and/or alopecia by new onset of hair loss after starting AZA; arthralgia when generalized joint ache or pain developed; and flulike symptoms. Patients with IBD were excluded for the analysis of gastrointestinal disorders.
Inflammatory response for patients with IBD. Serum CRP up to 5 mg/L, c-globulin up to 13.5 g/L, platelet count up to 600 9 10 9 /L, fibrinogen up to 4.3 g/L and WBC count above the reference ranges (table S1) were used as markers of inflammation.
Thiopurine metabolites, TPMT and ITPA assays. The 6-TGN and 6-MeMPN (including 6-MeTIMP, 6-MeTIDP and 6-MeTITP [48, 49] ) metabolite levels were determined in the RBCs using a previously described high-performance liquid chromatography method [50] . Metabolite concentrations were normalized to 8x10 8 RBCs. The therapeutic range for 6-TGN was considered as 250-450 pmol/ 8 9 10
8 RBCs [49] . The upper limit for 6-MeMPN was 6000 pmol/ 8 9 10
8 RBCs [49] . RBCs TPMT activity was assessed using the method developed by Boulieu et al. [51] . Patients with TPMT activity of 5, between 5 and 16, between 16 and 28, and ≥28 nmol/hr/mL RBCs were considered as low, intermediate, normal and high metabolizers, respectively.
ITPA activity was measured at each blood sampling in the same RBCs lysates used for TPMT assay. This method consisted of the enzymatic conversion of ITP to IMP as previously published by Citterio-Quentin et al. [52, 53] . ITPA activity was expressed as micromoles of IMP formed per gram of haemoglobin per hour (lmol IMP/g Hb/ hr). Subjects with ITPA activity of 5, between 5 and 34, between 34 and 70, and ≥70 lmol IMP/g Hb/hr were considered as low, intermediate, normal and high metabolizers, respectively, defining four ITPA phenotypes [30] .
Statistical analysis. Statistical analysis was performed using XLSTATâ version 2013.4.08 (Addinsoft, NC, USA) and R language version 3.4.2 available at https://cran.r-project.org. Data are described as median; range and/or n (%).
For statistical analysis, patients were classified in two groups: with ADRs and without ADRs. ITPA activity was compared between the two groups for each ADR using Mann-Whitney test, and the Spearman correlation coefficient (r s ) was used to assess relationships between ITPA activity and quantitative variables.
Furthermore, the cohort was categorized into four phenotype groups according to ITPA activity. Differences between phenotype groups were evaluated using Dunn's Kruskal-Wallis multiple comparisons test, and Fisher's exact test was performed to compare AE distribution between phenotype groups.
Multivariate statistical analyses were then conducted over the whole data set. To explore ITPA activity effect on ADRs, ADRs were classified as a whole by defining a binary variable 'Presence of at least one ADR' that took one when at least one ADR had occurred. Logistic regression models with logit-link function were fitted with 'Presence of at least one ADR' as dependent variable explained by the ITPA activity and covariates TPMT, 6-TGN and 6-MeMPN. Linear regression models were fitted to explain the MCV by the ITPA activity in the same way. For both models, effects of age and sex were tested, and models were adjusted for age and sex in case of significant effect. Explicative variables were added in the model using forward selection method, interactions were tested. Decimal log transformation was used for quantitative variables if necessary.
The effect of ITPA activity on inflammatory activity in children with IBD was investigated by fitting logistic regression models with 'Presence of inflammation' as dependent variable explained by the ITPA activity and covariates TPMT activity, 6-TGN and 6-MeMPN in the same above way.
Receiver operating characteristics (ROC) analyses were performed in turn for ITPA, TPMT activities, 6-TGN and 6-MeMPN to assess their predictive power on myelotoxicity occurrence using R package pROC and the 'closest topleft' method to estimate the optimal threshold. The area under the curve (AUC), optimal threshold, sensitivity, specificity, predictive positive and negative values were reported with their 95% confidence interval (CI). CIs were estimated by bootstrap resampling method with 10,000 replications.
p values <0.05 were considered statistically significant. In cases of multilevel comparisons, p values were calculated using Bonferroni correction.
Ethic statement. According to French legislation, no written consents are required for observational retrospective studies. All data were analysed anonymously. The ITPA assay was performed in the surplus blood sample remaining after TPMT assay, in accordance with institutional guidelines.
Results

Study patients.
We carried out a retrospective study in 106 children (57 males and 49 females) aged from 1.0 to 17.9 years (median 14 years) receiving AZA therapy for immunological diseases. Six patients were excluded for non-compliance. The clinical and demographic characteristics of subjects included in the study are shown in table 1.
Adverse drug reactions.
The most frequently observed adverse drug reaction was myelotoxicity which occurred in 51.4% of patients with a significant modification in RBC markers. Hepatotoxicity occurs in 12.7% of children, mainly due to an increase in APL level. The clinical ADR mainly observed is arthralgia (13.3%).
Some ADRs such as flulike symptoms, skin reactions and rise of AST/ALT, GGT or total bilirubin levels are poorly observed (<3%). No case of pancreatitis was reported.
Relation between adverse drug reactions and ITPA activity. The relations between ITPA activity and recorded adverse drug reactions are shown in table 2. When TPMT was taken into account, results were unchanged (data not shown).
ITPA activity is significantly higher in children with microcytosis (median ITPA activity: 51.1 versus 75.6 lmol IMP/g Hb/hr; adjusted p = 0.003; fig. 1A ). 54.5% (12/22) of subjects with microcytosis have high ITPA phenotype (Fisher's test; p < 0.0001).
Patients with low, intermediate, normal and high ITPA phenotype had a similar incidence of leucopenia, neutropenia and lymphopenia (Fisher's test; p = 0.453, 0.490 and 0.944, respectively) which confirms the lack of association between a decrease in WBC count, neutrophil count and lymphocyte count and ITPA activity. No relation was observed between ITPA activity and thrombocytopenia. The distribution of ITPA phenotype was not significantly different in children with hepatotoxicity compared with children without hepatotoxicity (Fisher's test; p = 0.724).
No significant difference in ITPA activity and in ITPA phenotype distribution between subjects with or without gastrointestinal disorders, cutaneous reactions, flulike symptoms and arthralgia was found.
Relationship between ITPA activity and inflammation markers in children with IBD. As shown in table 2 and fig. 1B , children with c-globulin higher than 13.5 g/L or platelet count above 600 9 10 9 /L exhibited higher ITPA activity than those with normal c-globulin or platelet count while ITPA activity was not modified in patients with CRP higher than 5 mg/L. However, this relationship with platelet count was not significantly after P value adjustment. Likewise, the distribution of ITPA phenotype groups was significantly different in children with a rise of cglobulin compared with patients without a rise of c-globulin: 53.3% (11/21) of patients with a rise of c-globulin have a high ITPA phenotype compared to 15.1% (8/43) of patients with no rise of c-globulin (Fisher's test; p = 0.019). To verify that the increase in c-globulins observed is not due to the injection of monoclonal antibody drugs, infliximab or adalimumab, a comparison in c-globulin level between patients with (n = 14)
or without (n = 50) monoclonal antibody was made and no significant difference was shown (median c-globulin level: 13.4 versus 12.5 g/L, respectively, p = 0.074). In addition, when patients with infliximab or adalimumab were excluded, ITPA activity between children with (n = 15) or without (n = 35) increased c-globulin levels stayed significantly different (p = 0.009). Likewise, to confirm that inflammation, reflected by an increase in c-globulin level, is not a cause of the increase in ITPA activity, we determined ITPA activity in 20 children not treated with AZA: 12 with and eight without high c-globulin level. No statistically significant difference was observed (median ITPA activity: 42.1 versus 55.9 lmol of IMP/g Hb/hr, respectively; p = 0.427) Bold characters correspond to significant statistical result. When TPMT was taken into account, all results were unchanged (data not shown).
Multivariate statistical analysis.
Values of normalized 6-TGN and 6-MeMPN were decimal log transformed to normalize their distribution. Sex and age showed an additive effect on MCV and only ITPA and 6-TGN entered additively in the final model adjusted for age and sex (R 2 = 47%). A 10-year increase in age provided in average a 5.3 increase (95% CI: 2.6-8.0) in MCV other things being equal, a 10-increase in ITPA activity provided an 1.1 decrease (95% CI: 0.6-1.5) in MCV and a 10-time higher 6-TGN level provided an 8.3 increase (95% CI: 4.6-12) in MCV. MCV was 2.4 (95% CI: 0.3-4.6) higher in females than in males. No variable had any significant effect on presence of at least one ADR.
Only ITPA activity exhibited a significant effect on the presence of at least one inflammation marker in children with IBD (n = 76). A 10-increase in ITPA activity multiplied the odds of inflammation presence by 1.6 (95% CI: 1.2-2.1).
The results of the ROC analyses are reported in table 3 and ROC curves in fig. 2 . ITPA activity seemed to be the most efficient predictor for myelotoxicity, but its AUC is only significantly different from the 6-MeMPN (p = 0.013).
Discussion
More data on the relationship between ITPA genotype and ADRs of thiopurine drugs have been reported in the literature [2, 3, [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] 26, [33] [34] [35] [36] [37] [38] [39] [40] [42] [43] [44] 54] . Some studies concerning the paediatric population are available [7, [10] [11] [12] [13] 15, 18, 22, 36, 37, 44, 54] with only two studies on paediatric patients with immune disease (IBD) [36, 44] . In paediatric populations, a relation between ITPA genotype with hepatotoxicity was reported in some studies [7, 11, 18] but not all [37] . In a paediatric population with acute lymphoblastic leukaemia, Stocco et al. [15] showed that ITPA genotype has a significant influence on the risk of fever and neutropenia, Hawwa et al. [22] reported a significant association between inosine triphosphatase IVS2+21A?C variants with thrombocytopenia, Hareedy et al. [13] found significant associations between ITPA singlenucleotide polymorphisms (SNPs) and haematological toxicity manifestations (neutropenia and leukopenia), Dorababu et al. [12] reported that TPMT and ITPA genotypes together can explain 27% of the variability in haematological toxicity, and Azimi et al. [11] showed that patients with aberrant ITPA genotype are more likely to be myelosuppressed after treatment with 6-MP. Concerning children with IBD, de Ridder et al. [36] detected no association of functional ITPA polymorphisms and the occurrence of AZA-related adverse drug reactions. Lee et al. [44] concluded that the rs1127354 SNP (94C>A) might be insignificant, but the number of patients of each phenotype was too small for this to be analysed in their study. Little data are available on the link between ITPA phenotype and adverse drug reactions which occurred in patients treated with thiopurine drugs, and no data from paediatric populations with immunological diseases are available. Shipkova et al. [2] reported an association between low ITPA activity and occurrence of leucopenia, and higher incidence of increased liver enzymes in adult IBD patients treated with azathioprine. Tanaka et al. [7] observed that patients with low ITPA activity presented hepatotoxicity more frequently than Table 3 . Area under the ROC curve, intrinsic and predictive characteristics on ITPA and TPMT activities, normalized 6-TGN or 6-MeMPN levels, respectively.
ITPA
TPMT 6-TGN 6-MeMPN those with higher activity during maintenance therapy for acute lymphoblastic leukaemia in Japanese children on 6-MP therapy. Xiong et al. [8] found that all three patients who have zero erythrocyte ITPA activity experienced AZA-related adverse effects (gastrointestinal toxicity, n = 2; flulike symptoms, n = 1). In our study, no significant association was found between ITPA activity and occurrence of flulike symptoms or skin reactions, arthralgia, alopecia and gastrointestinal disorders, but the number of cases reported in our cohort is low.
Regarding hepatotoxicity, no relation between deficiency in ITPA activity and hepatotoxic markers was observed. Concerning myelotoxic effects, no significant correlation was found between leukopenia, neutropenia, lymphopenia, thrombopenia, RBC count and ITPA phenotype. However, a difference in ITPA activity was observed between children with or without decreased MCV. This parameter was previously reported to be correlated with erythrocyte 6-TGN concentration in patients with IBD treated with AZA or 6-MP (r s = 0.33, p < 0.001) [58] . Using multivariate analysis, the correlation between MCV and normalized 6-TGN concentration and between MCV and ITPA activity was confirmed in our cohort. The difference in ITPA activity observed between children with or without decreased MCV with a threshold of ITPA activity of 62.6 micromole IMP/g Hb/hr could be linked with the significant relation found between high ITPA activity and high c-globulin level defined as inflammatory marker.
Furthermore, IBD children with a platelet count higher than 600 9 10 9 /L have an ITPA activity significantly higher than the others, but this finding was not significant after p value adjustment. Platelet elevation in the peripheral blood has been observed to be associated with intestinal inflammation in children with IBD [59] .
No difference was observed in ITPA activity in patients with high CRP compared to those with normal CRP values. A lack of correlation between serum CRP, biomarker of inflammation and clinical disease activity was recently reported in paediatric IBD patients [59] . This observation suggests that serum CRP will not be the best marker of inflammation in children with IBD. Likewise, the sensitivity of CRP was found poor and a negative test does not reliably exclude the presence of an active inflammation [62] . In our study, the lack of relation observed between the levels of CRP and ITPA activity would be in agreement with this hypothesis.
The association between ITPA activity and the increase in c-globulin level in children with IBD observed is particularly of interest because inflammation is postulated as a factor predisposing to disease relapse [60] . The reason why children on AZA therapy with high ITPA activity have more frequent inflammation is not elucidated, but the metabolism of AZA is very complex and the mechanism of action of thiopurine drugs is still not fully understood. This relationship should be further investigated.
In our cohort, TPMT activity had no influence on the relation between ITPA activity and ADRs.
Conclusion
As supported by several genotyping studies, no relation was demonstrated between ITPA phenotype and the occurrence of ADRs in our cohort including children on AZA therapy. The small frequency of some ADRs and the retrospective design are potential limitations of this study. However, a very significant relationship between high ITPA activity and c-globulin, an inflammation marker, was found in children with IBD. This observation suggests that the measurement of ITPA activity may help to identify children with IBD predisposed to residual inflammation, but further well-designed prospective studies are needed to confirm these results.
